(Q35927471)

11 August 2017

1 reference

title

What are the reasons for negative phase III trials of molecular-target-based drugs? (English)

1 reference

11 August 2017

main subject

phase III clinical trial

0 references

author name string

Nagahiro Saijo

series ordinal

1

1 reference

11 August 2017

language of work or name

1 reference

1 October 2004

1 reference

11 August 2017

1 reference

11 August 2017

volume

95

1 reference

11 August 2017

issue

10

1 reference

11 August 2017

page(s)

772-776

1 reference

Development of target-based antineoplastic agents

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2004.TB02180.X

Clinical trial design for target-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2004.TB02180.X

Dose escalation and pharmacokinetic study of irinotecan in combination with paclitaxel in patients with advanced cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2004.TB02180.X

Strategy for the development of novel anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2004.TB02180.X

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2004.TB02180.X

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2004.TB02180.X

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2004.TB02180.X

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2004.TB02180.X

Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the Europea

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2004.TB02180.X

Enhanced anti-tumor effect of trastuzumab in combination with cisplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2004.TB02180.X

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2004.TB02180.X

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2004.TB02180.X

Translational and clinical studies of target-based cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2004.TB02180.X

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2004.TB02180.X

10.1111/J.1349-7006.2004.TB02180.X

21 January 2018

Identifiers

DOI

1 reference

11 August 2017

1 reference